Journal of Hepatology
Volume 50, Issue 4 , Pages 684-692 , April 2009

Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients

  • Nicolás Merchante

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Ignacio de los Santos-Gil

      Affiliations

    • Servicio de Medicina Interna-Enfermedades Infecciosas, Hospital Universitario de La Princesa, Madrid, Spain
    • ,
  • Dolores Merino

      Affiliations

    • Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Mercedes González-Serrano

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Málaga, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • José A. Mira

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Jesús Sanz-Sanz

      Affiliations

    • Servicio de Medicina Interna-Enfermedades Infecciosas, Hospital Universitario de La Princesa, Madrid, Spain
    • ,
  • Elisa Fernández-Fuertes

      Affiliations

    • Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Josefa Ruiz-Morales

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Málaga, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • José del Valle

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Juan Macías

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    • ,
  • Antonio Moro

      Affiliations

    • Servicio de Análisis Clínicos, Hospital Universitario de Valme, Sevilla, Spain
    • ,
  • Juan A. Pineda

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Ctra. de Cadiz s/n, 41014 Sevilla, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 955015787/+34 955015747; fax: +34 955015747.
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

Received 23 September 2008 ,Revised 31 October 2008 ,Accepted 31 October 2008.

References 

  1. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663–1671
  2. Macias J, Melguizo I, Fernández-Rivera FJ, García-García JA, Mira JA, Ramos AJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2002;21:775–781
  3. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as major cause of death among HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805
  4. Pineda JA, García-García JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46:622–630
  5. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  6. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri E, et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA. 2004;292:2839–2848
  7. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459
  8. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–F36
  9. Moreno L, Quereda C, Moreno A, Pérez-Elias JM, Antela A, Casado JL, et al. Pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67–73
  10. Mira JA, Torre-Cisneros J, Merino D, Rios M, Collado A, Vergara S, et al. Efficacy of pegylated interferon plus ribavirin in HIV/HCV coinfection outside of well circumscribed clinical trials: the Andalusian multicenter study. In: 13th Conference on retroviruses and opportunistic infections, 22–25 February 2006, Denver, CO, USA. Abstract 861.
  11. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther. 2006;11:131–142
  12. Romero-Gómez M, del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–641
  13. D’Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100:1509–1515
  14. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Nezam HA, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80–87
  15. Palacios R, Merchante N, Macias J, González M, Castillo J, Ruiz J, et al. Incidence of and risk factors for insulin resistance in treatment–naı¨ve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther. 2006;11:529–535
  16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Tumer RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289–293
  18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374
  19. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Quantification of insulin resistance with the values of basal insulin and HOMA index in a non-diabetic population. Med Clin (Barc). 2001;117:530–533
  20. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320–3325
  21. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006;44:335–340
  22. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403–410
  23. Toyoda H, Kumuda T. Cholesterol and lipoproteins levels as predictors of response to interferon for hepatitis C. [Letter] Ann Intern Med. 2000;133:921
  24. Minuk GY, Weinstein S, Kaita KD. Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C. [Letter] Ann Intern Med. 2000;132:761–762
  25. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Population-based incidence rates and risks factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53:1782–1789
  26. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177–1186
  27. Rodríguez-Torres M, Govindarajan S, Solá R, Clumeck N, Lissen E, Pessoa M. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy. A paired liver biopsy study. J Hepatol. 2008;48:756–764
  28. Opravil M, Sasadeusz J, Cooper DA, Rockstroh J, Clumeck N, Clotet B, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008;47:36–49
  29. Pineda JA, Mira JA, de los Santos I, Valera-Bestard V, Rivero A, Merino D, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virologic response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother. 2007;60:1347–1354
  30. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429–437
  31. Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de los Santos I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus-coinfected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 2008;62:1365–1373
  32. Nasta P, Gatti F, Puoti M, Cologni G, Bergamaschi V, Borghi F, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS. 2008;22:857–861
  33. del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, et al. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS. 2008;22:923–930
  34. Monazahian M, Bohme I, Bonk S, Koch A, Scholz S, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol. 1999;57:223–229
  35. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766–12771
  36. Enjoji M, Nakamuta M, Kinukawa N, Sugimoto R, Noguchi K, Tsuruta S, et al. Beta-lipoproteins influence the serum level of hepatitis C virus. Med Sci Monit. 2000;6:841–844

☆ The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the drugs involved either in the past or present and they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00806-4

doi: 10.1016/j.jhep.2008.10.032

Journal of Hepatology
Volume 50, Issue 4 , Pages 684-692 , April 2009

Article Tools

* Image Usage & Resolution